First Phase III trial of an alpha-pharmaceutical

Until recently, options for patients with bone metastases from advanced prostate cancer have been very limited. But now the first Phase III study of an alpha-pharmaceutical in these patients has shown that it can prolong survival significantly, according to research reported today (Saturday) at the 2011 European Multidisciplinary Cancer Congress.

Read the whole article on Physorg

More from Physorg